MedPath

Study of skin features, laboratory features and response to treatment to antifungal drugs in patients with superficial fungal infections.

Not Applicable
Conditions
Health Condition 1: null- EXTENSIVE DERMATOPHYTIC INFECTIONS
Registration Number
CTRI/2018/04/013045
Lead Sponsor
MAHARAJAHS INSTITUTE OF MEDICAL SCIENCES
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Clinically diagnosed cases of extensivedermatophytoses infection affecting more than one region of the body.

2. Both sexes between the age groups 18 - 70 yrs

3.Patients who have not used topical and systemic antifungal drugs for the past 6 weeks.

Exclusion Criteria

1.Infants, below 18 yrs, above 70 yrs

2.Immunocompromised patients including HIV are excluded.

3.Pregnancy and lactating patients are excludued.

4.Patients receiving multiple drugs for medical conditions including glucocorticosteroids.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Cinical profile of dermatophytic infections prevalent in this region will be noted. <br/ ><br>2.Mycological profile of dermatophytic infections including species identification prevalent in this region will be noted. <br/ ><br>3.Sensitivity pattern of isolates against terbinafine, itraconazole,griseofulvin will be studied and recorded. <br/ ><br>4.Therapeutic efficacy of single and in combinations of systemic antifungal drugs in extensive dermatophytic infections will be reported. <br/ ><br> <br/ ><br>Timepoint: 8 weeks <br/ ><br> <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
1. To note the recurrences in the follow up period of 6 months.Timepoint: 6 months
© Copyright 2025. All Rights Reserved by MedPath